Therapeutics Solutions International, Inc. announced today the development of a cytokine-based diagnostic kit aimed at stratifying risk of preterm labor and other pregnancy-associated complications.
The approach is covered by patent application No. 62/219020, filed on September 15, 2015, which was developed out of intellectual property purchased from OmniBiome Therapeutics Inc.
“The current patent filing is a continuation of the company’s focus on leveraging immunological processes to diagnose and intervene in niche areas of unmet medical needs,” said Timothy Dixon, President and CEO of Therapeutic Solutions International.
Mr. Dixon added, “Specific biological molecules termed cytokines that are involved in the immune system killing cancer also appear to be involved in stimulating preterm labor and in extreme cases pregnancy loss. In our previous patent filings we cover means of modulating these molecules, either to fight cancer, or to prevent pregnancy complications. In the current patent filing we utilize advanced techniques to detect modulations of these molecules in the body, so as to potentially interfere at an early stage and hopefully preserve a healthy pregnancy.”
The company currently is marketing ProJuvenol, a pterostilbene based nutraceutical, which has been demonstrated by independent groups to modulate cytokines such as TNF-alpha and interleukin-1, which are involved in pregnancy complications. Additionally, the company reported data showing its probiotic mixture is effective at reducing pregnancy loss in a mouse model of immunologically mediated miscarriage.
“We aim to create products that on the one hand assist the physician at identifying potential pregnancy problems early, when intervention conceptually is more effective, as well as products that may modulate the biological cascades which lead to pregnancy complications. Currently we are seeking clinical collaborators and partners to accelerate the development of our approaches” said Mr. Dixon.
